Basal Cell Carcinoma Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

The market dynamics for Basal Cell Carcinoma (BCC) are anticipated to witness notable growth driven by the increasing incidence of BCC, heightened UV exposure, aging population, growing awareness regarding early diagnosis, and the launch of emerging therapies. Additionally, the development of promising therapies such as LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), STP705 (Sirnaomics), and others will further support the market expansion.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Basal Cell Carcinoma (BCC) Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Basal Cell Carcinoma, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Basal Cell Carcinoma Market

*
The market size for Basal Cell Carcinoma in the leading markets is expected to increase significantly during the forecast period 2022-2036.

*
The United States accounted for the highest Basal Cell Carcinoma market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.

*
According to the Skin Cancer Foundation (2023), BCC is the most common form of skin cancer, with an estimated 3.6 million cases diagnosed annually in the United States.

*
According to the American Cancer Society (2023), approximately 5.4 million basal and squamous cell skin cancers are diagnosed each year in about 3.3 million persons in the US, with nearly 80% of those cases being BCCs.

*
A 2025 JAMA Dermatology study based on Global Burden of Disease (GBD) 2021 data estimated approximately 2.8 million incident BCC cases globally in 2021, making it the most common skin cancer worldwide.

*
According to Roky et al. (2025), approximately 700,000 new BCC cases are diagnosed annually in Europe, with incidence rates continuing to increase by nearly 5.5% per year.

*
Leading BCC companies such as Lytix Biopharma, Verrica Pharmaceuticals, Sirnaomics, Stamford Pharmaceuticals, Philogen, Sun Pharmaceutical, Medivir/Biossil, and others are developing novel BCC treatment approaches to improve patient outcomes.

*
Promising Basal Cell Carcinoma pipeline therapies include LTX-315/VP-315, STP705, SP-002, Remetinostat, NIDLEGY, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Basal Cell Carcinoma Market

Increasing Incidence of BCC and UV Exposure:Rising exposure to ultraviolet (UV) radiation, lifestyle changes, and an aging population are major contributors to the increasing incidence of BCC globally. Growing awareness and improved diagnosis rates are further increasing treatment demand.

Growing Adoption of Targeted and Immunotherapy Approaches:Targeted Hedgehog pathway inhibitors (HHPIs) such as vismodegib and sonidegib, along with immunotherapies like cemiplimab, are significantly improving outcomes in advanced and locally advanced BCC patients.

Advancements in Non-surgical and Topical Therapies:The increasing use of topical therapies, photodynamic therapy, and emerging non-surgical treatment options is expanding the therapeutic landscape for patients unsuitable for surgery.

Basal Cell Carcinoma Competitive Landscape

*
Several BCC therapies in development include LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), Remetinostat (Medivir/Biossil), and NIDLEGY (Philogen/Sun Pharmaceutical).

*
These therapies target diverse mechanisms such as oncolytic peptide immunotherapy, TGF-Ss1/COX-2 inhibition, adenovirus-mediated interferon-gamma delivery, and histone deacetylase inhibition to improve treatment efficacy and provide alternatives to invasive surgical approaches.

Discover more about therapies set to grab major Basal Cell Carcinoma market share @ Basal Cell Carcinoma Treatment Landscape [https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Basal Cell Carcinoma Market

*
In April 2026, Verrica Pharmaceuticals announced that a late-breaking abstract on VP-315 (ruxotemitide) was accepted for presentation at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, highlighting Phase II exploratory data supporting its immunologic activity and non-surgical treatment potential.

*
In March 2025, Verrica Pharmaceuticals received positive FDA feedback from the end-of-Phase II meeting supporting an efficient Phase III program and registration pathway for VP-315 in BCC.

*
In January 2025, Stamford Pharmaceuticals announced positive Phase IIa trial results for SP-002 in combination with vismodegib in subjects with multiple BCCs.

*
Stamford Pharmaceuticals also announced plans to initiate Phase III development of SP-002 for BCC during 2H 2025/1H 2026.

*
Sirnaomics reported encouraging Phase II clinical study results for STP705 demonstrating strong efficacy without significant drug-related adverse effects in BCC treatment.

What is Basal Cell Carcinoma (BCC)?

Basal Cell Carcinoma (BCC), previously known as basal cell epithelioma, is the most common form of skin cancer and among the most frequently diagnosed cancers worldwide. BCC is generally a slow-growing and locally invasive tumor that rarely metastasizes.

BCC commonly develops on sun-exposed areas of the skin and is strongly associated with cumulative ultraviolet radiation exposure. Common treatment approaches include surgical excision, Mohs micrographic surgery, topical therapies, radiation therapy, cryotherapy, photodynamic therapy, and systemic therapies for advanced disease.

FDA-approved therapies for advanced BCC include cemiplimab (LIBTAYO), vismodegib (ERIVEDGE), and sonidegib (ODOMZO).

Basal Cell Carcinoma Epidemiology Segmentation

The Basal Cell Carcinoma epidemiology section provides insights into the historical and current BCC patient pool and forecasted trends for the leading markets. The Basal Cell Carcinoma market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Incident Cases of Non-Melanoma Skin Cancer

*
Total Incident Cases of BCC

*
Subtype-specific Incident Cases of BCC

*
Stage-specific Incident Cases of BCC

*
Line-wise Treated Cases of BCC

Scope of the Basal Cell Carcinoma Market Report

*
Therapeutic Assessment: Basal Cell Carcinoma current marketed and emerging therapies

*
Basal Cell Carcinoma Market Dynamics: Key Market Forecast Assumptions and Market Outlook

*
Key Companies: Lytix Biopharma, Verrica Pharmaceuticals, Sirnaomics, Stamford Pharmaceuticals, Philogen, Sun Pharmaceutical, Medivir/Biossil, and others

*
Key Therapies: LTX-315/VP-315, STP705, SP-002, Remetinostat, NIDLEGY, LIBTAYO, ODOMZO, ERIVEDGE, and others

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Basal Cell Carcinoma Market Access and Reimbursement

To know more about Basal Cell Carcinoma companies working in the treatment market, visit @ Basal Cell Carcinoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Basal Cell Carcinoma Market Report Introduction

*
Executive Summary for Basal Cell Carcinoma

*
SWOT Analysis of Basal Cell Carcinoma

*
Basal Cell Carcinoma Patient Share (%) Overview at a Glance

*
Basal Cell Carcinoma Market Overview at a Glance

*
Basal Cell Carcinoma Background and Overview

*
Basal Cell Carcinoma Epidemiology and Patient Population

*
Country-Specific Patient Population of Basal Cell Carcinoma

*
Basal Cell Carcinoma Current Treatment and Medical Practices

*
Basal Cell Carcinoma Unmet Needs

*
Basal Cell Carcinoma Emerging Therapies

*
Basal Cell Carcinoma Market Outlook

*
Country-Wise Basal Cell Carcinoma Market Analysis (2022-2036)

*
Basal Cell Carcinoma Market Access and Reimbursement of Therapies

*
Basal Cell Carcinoma Market Drivers

*
Basal Cell Carcinoma Market Barriers

*
Basal Cell Carcinoma Appendix

*
Basal Cell Carcinoma Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=basal-cell-carcinoma-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-disease-burden-and-emerging-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.